Jessica Hergert | Authors

No Improvement in EFS for Aggressive B-cell NHL Noted With Second-line Tisagenlecleucel

December 13, 2021

Patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma did not benefit in terms of event-free survival when treated with the CAR T-cell therapy tisagenlecleucel vs standard-of-care chemotherapy and transplant.

Real-World Results for Tisagenlecleucel in R/R B-Cell Non-Hodgkin Lymphomas Hold Up to JULIET Data

December 12, 2021

Treatment with the CAR T-cell therapy tisagenlecleucel for relapsed or refractory diffuse large B-cell lymphoma or high-grade B-cell lymphoma was favorable in both the pivotal clinical trial and the real-world setting, according to new data made available during 2021 ASH.

Durvalumab Demonstrates Real-World PFS Benefit In Unresectable Stage III NSCLC

September 22, 2021

Findings from the PACIFIC-R trial indicated that the real-world progression-free survival benefit of durvalumab was higher vs the median progression-free survival reported in the durvalumab arm of the phase 3 PACIFIC trial in unresectable stage III non–small cell lung cancer.